Axio BioPharma Teams With Shimadzu on Media Optimization
Axio BioPharma and Shimadzu Corporation are combining AI-guided cell culture media optimization with laboratory experimentation in Madison.
Updated on Nov. 6, 2026 in Biotech
Axio BioPharma, a biomanufacturing technology company, is collaborating with Shimadzu Corporation on cell culture media optimization. The teams will combine Shimadzu's CellTune Ver.2 software and Media Blending Kit with Axio's expression and laboratory capabilities in Madison, Wisconsin.
Why it matters
Optimizing cell culture media requires evaluating many variables while balancing productivity, development timelines, and experimental resources. Traditional trial-and-error approaches can demand significant laboratory time and multiple rounds of experimentation.
The announcement describes an integrated workflow in which CellTune Ver.2 software proposes culture conditions that are then tested in Axio's Madison laboratory. No performance metrics were disclosed, and the companies have not published outcome data.
The players
Axio BioPharma
Axio BioPharma is a biomanufacturing technology company based in Madison, Wisconsin, focused on expression and laboratory services for biologics development.
Shimadzu Corporation
Shimadzu Corporation is a Japanese global manufacturer of analytical and measurement instruments, including diagnostics and cell culture analysis products.
Justin Byers
Justin Byers is the founder and chief executive officer of Axio BioPharma.
Toru Ezure
Toru Ezure is business unit director of the cell business unit in Shimadzu Corporation's diagnostics division.
The details
CellTune Ver.2 uses statistical analysis and AI to optimize cell culture conditions, while the Media Blending Kit prepares defined combinations of supplements and base media for testing. Axio's Madison laboratory will run media optimization studies within antibody expression workflows, with the teams evaluating the connected process end to end.
Timeline
The collaboration was announced without a specified start date or milestone schedule.
The Tech Race
The collaboration extends traditional Design of Experiments methods used in bioprocess media development by pairing AI-guided condition proposals with physical testing. It positions AI-assisted optimization as a practical complement to the statistical screening long used in biologics manufacturing.
For readers following biologics, the collaboration may eventually shorten the time needed to find effective culture media for antibody production. No consumer-facing products or changes have been announced.
The takeaway
Combining AI-guided suggestions with hands-on lab testing reflects a broader effort to reduce the trial-and-error cycles that slow biologics development. Results from this partnership will show whether the approach delivers measurable gains.
Further reading
For related coverage, explore more Biotech developments in Madison.
Source note: This article includes information reported by Scientist Live.
